Collegium Pharmaceutical Stock News

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are MELI, ACLS, SHG, PDD and COLL.

RGA, JBL, LBRT, CGAU and COLL are a few high earnings yield value stocks that could be good additions to your portfolio now.

COLL vs. ZTS: Which Stock Is the Better Value Option?

My Collegium Pharmaceutical position has been gathering thanks to the ticker trading between my Buy and Sell Targets. The company's Q3 earnings beat has forced me to update my strategy. Collegium's ne

Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Dawn Schottlandt - Managing Director-Argot Partners Joe Ciaffoni - Chief

STOUGHTON, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that it will report third q

Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the nea

Last week, Collegium Pharmaceutical Inc (NASDAQ: COLL) reported Q2 results—the first full quarter with BioDelivery—and beat revenue and EBITDA estimates.  HC Wainwright has downgraded the sto

Upgrades For iRobot Corp (NASDAQ:IRBT), JP Morgan upgraded the previous rating of Underweight to Neutral. In the second quarter, iRobot showed an EPS of $0.35, compared to $0.27 from the year-ago qua

Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Alex Dasalla - Head, IR Joseph Ciaffoni - CEO Colleen Tupper - CFO Scott Dr

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -90.08% and 0.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -90.08% and 0.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock

Xencor (XNCR) delivered earnings and revenue surprises of -26.67% and 12.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

STOUGHTON, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that it will report second